Pacing-induced heart failure: A model to study the mechanism of disease progression and novel therapy in heart failure

Cardiovascular Research

Volumn 42, Issue 3, 1999, Pages 591-599

  Moe, Gordon W ^a,b   Armstrong, Paul ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cytokines; Endothelins; Heart failure; Natriuretic peptides; Ventricular function

Indexed keywords

CYTOKINE; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; MATRIX METALLOPROTEINASE; N(G) NITROARGININE METHYL ESTER; NEUROHORMONE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

CELL LOSS; CONGESTIVE HEART FAILURE; DISEASE COURSE; EXTRACELLULAR MATRIX; FLUID RETENTION; HEART MUSCLE CELL; HEART PACING; HEART VENTRICLE REMODELING; HEMODYNAMICS; HUMAN; LUNG CONGESTION; LUNG EDEMA; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIAC PACING, ARTIFICIAL; CYTOKINES; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; NEUROTRANSMITTER AGENTS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II;

EID: 0032994303     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00032-2     Document Type: Review

References (79)

1. Cowie M.R., Mostend A., Wood D.A., et al. The epidemiology of heart failure. Eur Heart J. 18:1997;208-225.
2. Rich M.W., Freedland K.E. Effect of DRGs on three-month readmission rate of geriatric patients with congestive heart failure. Am J Public Health. 78:1988;680-682.
3. O'Connell J.B., Bristow M.R. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 13:1994;S107-S112.
4. Davies C.H., Harding S.E., Poole-Wilson P.A. Cellular mechanisms of contractile dysfunction in human heart failure. Eur Heart J. 17:1996;189-198.
5. Packer M. The neurohormone hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 20:1992;248-254.
6. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation. 92:1995;1379-1382.
7. McMurray J., McKay J., Chopra M., Bridges A., Belch J.J.F. Evidence for free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 65:1990;1261-1262.
8. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 335:1996;1182-1189.
9. Eichhorn E.J., Bristow M. Medical therapy can improve the biological properties of the chronically failing heart. Circulation. 94:1996;2285-2296.
10. Smith H.J., Nuttall A. Experimental models of heart failure. Cardiovasc Res. 19:1985;181-186.
11. Gross D.R. Iatrogenic models for studying heart disease. Gross D.R. Animal models of cardiovascular research. 1994;421-429 Kluwer Academic Publishers, Norwall, MA.
12. Elsner D., Riegger G.A.J. Characteristics and clinical relevance of animal models of heart failure. Curr Opin Cardiol. 10:1995;253-259.
13. Whipple GH, Sheffield LT, Woodman EG, Thoephilis C, Friedman S. Reversible congestive heart failure due to rapid stimulation of the normal heart. In: Proc New Engl Cardiovasc Soc. 1961-1962;20:39-40.
14. Armstrong P.W., Stopps T.P., Ford S.E., DeBold A.J. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation. 74:1986;1075-1084.
15. Riegger A.J., Liebau F. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci. 62:1982;465-469.
16. Howard R.J., Moe G.W., Stopps T.P., Armstrong P.W. Recovery from heart failure: structural and functional analysis in a canine model. Can J Physiol Pharmacol. 66:1988;1505-1512.
17. Moe G.W., Stopps T.P., Howard R.J., Armstrong P.W. Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing-induced heart failure. J Lab Clin Med. 112:1988;426-432.
18. Armstrong P.W., Howard R.J., Moe G.W. Clinical lessons learned from experimental heart failure. Int J Cardiol. 24:1989;133-136.
19. Armstrong P.W., Moe G.W. The development of and recovery from pacing-induced heart failure. Spinale F.G. Pathophysiology of tachycardia-induced heart failure. 1996;45-59 Futura Publishing Company, Armonk, NY.
20. Shinbane J.S., Wood M.A., Jensen N., et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 29:1997;709-715.
21. Moe G.W., Stopps T.P., Angus C., et al. Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure. J Am Coll Cardiol. 13:1989;173-179.
22. Moe G.W., Legault L., Skorecki K.L. Control of extracellular fluid volume and pathophysiology of edema formation. Brenner B.M., Rector F.C. The kidney. 4th ed. 1991;649-652 WB Saunders, Philadelphia, PA.
23. Stevens T.L., Borgeson D.D., Luchner A., et al. A modified model of tachycardia-induced cardiomyopathy: insights into humoral and renal adaptations. Spinale F.G. Pathophysiology of tachycardia-induced heart failure. 1996;133-151 Futura Publishing Company, Armonk, NY.
24. Stevens T.L., Rasmussen T.E., Wei C.M., et al. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure. J Cardiac Failure. 2:1996;119-125.
25. Moe G.W., Grima E.A., Wong N.L.M., Howard R.J., Armstrong P.W. Dual natriuretic peptide system in experimental heart failure. J Am Coll Cardiol. 22:1993;891-898.
26. Moe G.W., Forster C., de Bold A.J., Armstrong P.W. Pharmacokinetics, hemodynamic, renal, and neurohormonal effects of atrial natriuretic factor in experimental heart failure. Clin Invest Med. 13:1990;111-118.
27. Fu Y., O'Brien D.W., Chan S.Y., et al. Does a hypertonic saline load predict fluid retention in pacing induced heart failure? Cardiovasc Res. 33:1997;172-180.
28. Spinale F.G., Hendrick D.A., Crawford F.A., et al. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol. 259:1990;H218-H229.
29. Morgan D.E., Tomlinson C.W., Qayumi A.K., et al. Evaluation of ventricular contractility indexes in the dog with left ventricular dysfunction induced by rapid atrial pacing. J Am Coll Cardiol. 14:1989;489-495.
30. Tanaka R., Spinale F.G., Crawford F.A., Zile M.R. Effect of chronic supraventricular tachycardia on left ventricular function and structure in newborn pigs. J Am Coll Cardiol. 20:1992;1650-1660.
31. Shannon R.P., Komamura K., Stambler B.S., et al. Alterations in myocardial contractility in conscious dogs with dilated cardiomyopathy. Am J Physiol. 260:1991;H1903-H1911.
32. Tomita M., Spinale F.G., Crawford F.A., Zile M.R. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. Circulation. 83:1991;635-644.
33. Moe G.W., Montgomery C., Howard R.J., Grima E.A., Armstrong P.W. Left ventricular myocardial blood flow, metabolism, and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. J Lab Clin Med. 121:1993;294-299.
34. Moe G.W., Howard R., Grima E.A., Armstrong P.W. How does intermittent pacing modify the response to rapid ventricular pacing in experimental heart failure? J Cardiac Failure. 1:1995;223-228.
35. Osler W. The principles and practice of medicine. 1892;D. Appleton and Company, New York.
36. Moe G.W., Grima E.A., Howard R.J., Armstrong P.W. Biatrial appendage hypertrophy but not ventricular hypertrophy: a unique feature of canine pacing-induced heart failure. J Cardiac Failure. 2:1996;127-131.
37. O'Brien D.W., Fu Y., Parker H.R., et al. Differential morphometric and ultra-structural remodeling in canine left atrium and ventricle after rapid ventricular pacing. Can J Cardiol. 14:1998;99F. abstract.
38. Spinale F.G., Zellner J.L., Tomita M., Crawford F.A., Zile M.R. Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res. 69:1991;1058-1067.
39. Eble D.M., Spinale F.G. Effects of chronic supraventricular tachycardia on contractile and non-contractile mRNA expression: relation to changes in myocyte structure and function. Am J Physiol. 268:1995;H2426-H2439.
40. Spinale F.G., Fulbright B.M., Mukherjee R., et al. Relationship between ventricular and myocyte function with tachycardia induced cardiomyopathy. Circ Res. 71:1992;174-187.
41. Spinale F.G., Temple G.E., Mukherjee R., et al. Cellular and molecular changes in the β-adrenergic system with supraventricular tachycardia induced cardiomyopathy. Cardiovasc Res. 28:1994;1243-1250.
42. Moe G.W., Howard R.J., Parker T.G., Armstrong P.W. Evaluation of indices of left ventricular contractility and relaxation in evolving canine experimental heart failure. Cardiovasc Res. 26:1992;362-366.
43. Moe G.W., Grima E.A., Howard R.J., Seth R., Armstrong P.W. Left ventricular remodeling and disparate changes in contractility and relaxation during the development of and recovery from experimental heart failure. Cardiovasc Res. 28:1994;66-71.
44. Kajstura J., Zhang X., Liu Y., et al. The cellular basis of pacing-induced dilated cardiomyopathy; myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation. 92:1995;2306-2317.
45. Stewart B.W. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst. 86:1994;1286-1296.
46. Arends M.J., Myllie A.H. Apoptosis: mechanisms and roles in pathology. Int Rec Exp Pathol. 32:1991;223-254.
47. Tanaka M., Ito H., Adachi S., et al. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res. 75:1994;426-433.
48. Nagata S., Goldstein P. The Fas death factor. Science. 267:1995;1449-1456.
49. Yonish-Rouach E., Resnitzky D., Lotem J., et al. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature. 352:1991;345-347.
50. Leri A., Liu Yu. Malhotra A., et al. Pacing-induced heart failure in dogs enhances the expression of p53 and p53-dependent genes in ventricular myocytes. Circulation. 97:1998;194-203.
51. Moe G., Konig A., Naik G., Feng Q. Early activation of programmed cell death may contribute to heart failure progression. Can J Cardiol. 14:1998;184F. abstract.
52. Janicki J.S., Matsubara B.B. Myocardial collagen and left ventricular diastolic dysfunction. Gaash W.H., LeWinter M.M. Left ventricular diastolic dysfunction and heart failure. 1994;125-140 Lea and Febiger, Philadelphia, PA.
53. Weber K.T., Pick R., Silver M.A., et al. Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation. 82:1990;1387-1401.
54. Komamura K., Shannon R.P., Pasipoularides A., et al. Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure. J Clin Invest. 89:1992;1825-1838.
55. Spinale F.G., Tomita M., Zellner J.L., et al. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 261:1991;H308-H318.
56. Armstrong P.W., Moe G.W., Howard R.J., Grima E.A., Cruz T.F. Structural remodeling in heart failure: gelatinase induction. Can J Cardiol. 10:1994;214-220.
57. Spinale F.G., Coker M.L., Thomas C.V., et al. Time dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 82:1998;482-495.
58. Parker H.R., Scott P.G., Bleackley C.R., et al. Matrix metalloproteinase alterations in the canine atrium and ventricle during rapid ventricular pacing. J Am Coll Cardiol. 29:1997;244A. abstract.
59. Spinale F.G., Krombach S., Coker M.L., Boyce S. Matrix metalloproteinase inhibition with congestive heart failure improves left ventricular geometry and pump function. Circulation. 96:1997;I520. abstract.
60. Dupuis J., Moe G.W., Cernacek P. Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure. Cardiovasc Res. 39:1998;609-616.
61. Elsner D., Riegger G.A.J. Characteristics and clinical relevance of animal models of heart failure. Curr Opin Cardiol. 10:1995;253-259.
62. Yanigasawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
63. Colucci W.S. Myocardial endothelin. Does it play a role in myocardial failure? Circulation. 93:1996;1069-1072.
64. Marguiles K.B., Hilbdebrand F.L. Jr., Lerman A., Perella M.A., Burnett J.C. Jr. Increased endothelin in experimental heart failure. Circulation. 82:1990;2226-2230.
65. Huntington K., Picard P., Moe G.W., et al. Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure. J Cardiovasc Pharmacol. 31:1998;S424-S426.
66. Moe G.W., Ferrazi S., Naik G., Howard R.J. Endothelin in heart failure: temporal evolution, source of production and interaction with atrial natriuretic peptide. Circulation. 90:1994;I503. abstract.
67. Cody R.J., Haas G.J., Binkley P.F., Capers Q., Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
68. Moe G.W., Albernaz A., Naik G., Kirchengast M., Stewart D.J. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Cardiovasc Res. 39:1998;571-579.
69. Spinale F.G., Walker J., Mukhejee R., et al. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation. 95:1997;1918-1929.
70. Mann D.L., Young J.B. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest. 105:1994;897-904.
71. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
72. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 92:1995;1479-1486.
73. Moe G.W., Qu A., Albernaz A., Naik G., Liu P. What is the source of increased myocardial tumor necrosis factor-alpha in heart failure. J Am Coll Cardiol. 31:1998;289A. abstract.
74. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart is mediated by nitric oxide. Science. 257:1992;387-389.
75. Brady A.J.B., Warren J.B., Poole-Wilson P.A., Williams T.J., Harding S.E. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol. 265:1993;H176-H182.
76. Hare J.M., Colucci W.S. Role of nitric oxide in the regulation of myocardial function. Prog Cardiovasc Dis. 38:1995;155-166.
77. Yamamoto S., Tsutsui H., Tagawa H., et al. Role of myocyte nitric oxide in β-adrenergic hyporesponsiveness in heart failure. Circulation. 95:1997;1111-1114.
78. Khadour F.H., O'Brien D.W., Fu Y., Armstrong P.W., Schulz R. Endothelial nitric oxide synthase increases in left atria of dogs with pacing-induced heart failure. Am J Physiol. 275:1998;7971-7978.
79. O'Murchu B., Miller V.M., Perrella M.A., Burnett J.C. Jr. Increased production of nitric oxide in coronary arteries during congestive heart failure. J Clin Invest. 93:1994;65-71.